跳轉至內容
Merck
全部照片(1)

Key Documents

420099

Millipore

JAK抑制剂I

≥98% (HPLC), solid, JAK inhibitor, Calbiochem®

同義詞:

Janus蛋白酪氨酸激酶(JAK)抑制剂I, 2-(1,1-二甲基乙基)-9-氟-3,6-二氢-7H-苯并[h]-咪唑[4,5-f]异喹啉-7-酮,吡啶酮6,P6,DBI,JAK1抑制剂I,JAK2抑制剂I,JAK3抑制剂X

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C18H16FN3O
CAS號碼:
分子量::
309.34
分類程式碼代碼:
12352200
NACRES:
NA.77

product name

JAK抑制剂I, JAK Inhibitor I, CAS 457081-03-7, is a potent, reversible, cell-permeable, and ATP-competitive inhibitor of JAK 1 (IC₅₀ = 15 nM), JAK2 (IC₅₀ = 1 nM), JAK3 (Ki = 5 nM) and Tyk2 (IC₅₀ = 1 nM).

品質等級

化驗

≥98% (HPLC)

形狀

solid

製造商/商標名

Calbiochem®

儲存條件

OK to freeze
protect from light

顏色

off-white

溶解度

DMSO: 5 mg/mL

運輸包裝

ambient

儲存溫度

−20°C

InChI

1S/C18H16FN3O/c1-18(2,3)17-21-14-10-5-4-9(19)8-12(10)13-11(15(14)22-17)6-7-20-16(13)23/h4-8H,1-3H3,(H,20,23)(H,21,22)

InChI 密鑰

VNDWQCSOSCCWIP-UHFFFAOYSA-N

一般說明

一种有效、可逆、细胞可渗透和ATP竞争性的Janus蛋白酪氨酸激酶(JAKs)抑制剂。显示对JAK1(对于鼠JAK1,IC50=15 nM)、JAK2(IC50=1 nM)、JAK3(Ki=5 nM)和Tyk2(IC50=1 nM)的有效抑制活性。在高得多的浓度下抑制其他激酶。显示抑制IL2和IL4依赖性的CTLL细胞增殖,并阻断STAT5的磷酸化;并且与AG 490(目录编号658401)不同,进一步诱导表达活化的JAKs和STAT3的多发性骨髓瘤细胞的生长抑制。也可获得10 mM(500 µg/162 µl)JAK抑制剂I的DMSO溶液(目录号420097)。
一种有效、细胞可渗透、可逆和ATP竞争性的Janus蛋白酪氨酸激酶(JAKs)抑制剂。显示对JAK1(对于鼠JAK1,IC50=15 nM)、JAK2(IC50=1 nM)、JAK3(Ki=5 nM)和Tyk2(IC50=1 nM)的有效抑制活性。在高得多的浓度下抑制其他激酶。显示抑制IL2和IL4依赖性的CTLL细胞增殖,并阻断STAT5的磷酸化;并且与AG 490(目录编号658401)不同,进一步诱导表达活化的JAKs和STAT3的多发性骨髓瘤细胞的生长抑制。

生化/生理作用

主要靶标
鼠JAK1
产物与ATP竞争。
可逆性:是
细胞可渗透性:是
靶标IC50:15 nM,针对鼠JAK1;1 nM,针对JAK2;1 nM,针对Tyk2
靶标Ki:5 nM,针对JAK3

包裝

用惰性气体包装

警告

毒性:标准处理(A)

重構

复溶后,等分并冷冻(-20°C)。储备溶液在-20°C下可稳定保存至多3个月。

其他說明

Pedranzini, L., et al. 2006.Cancer Res.66, 9714.
Lucet, I.S., et al. 2005.Blood107, 176.
Thompson, J.E., et al. 2002.Bioorg.Med. Chem. Lett.12, 1219.

法律資訊

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Ian C Henrich et al.
Cancer research, 81(8), 2171-2183 (2021-02-10)
Ewing sarcoma is the second most common pediatric bone cancer, with a 5-year survival rate for metastatic disease of only 20%. Recent work indicates that survival is strongly correlated with high levels of tumor-infiltrating lymphocytes (TIL), whose abundance is associated
Dongbum Kim et al.
BMB reports, 54(8), 425-430 (2021-04-10)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces coronavirus disease 2019 (COVID-19) and may increase the risk of adverse outcomes in lung cancer patients. In this study, we investigated the expression and function of mucin 1 (MUC1) after SARS-CoV-2 infection
Fuyuko Takata et al.
Journal of cellular biochemistry, 119(11), 9055-9063 (2018-08-05)
Oncostatin M (OSM) is a member of the interleukin (IL)-6 family cytokines. We previously demonstrated that OSM induces blood-brain barrier (BBB) impairment. However, functional characterization of IL-6 family cytokines in BBB regulation and the cytokine-related intracellular signaling pathway remain unclear.
Hannah M Burgess et al.
Genes & development, 35(13-14), 1005-1019 (2021-06-26)
N6-methyladenosine (m6A) is an abundant internal RNA modification, influencing transcript fate and function in uninfected and virus-infected cells. Installation of m6A by the nuclear RNA methyltransferase METTL3 occurs cotranscriptionally; however, the genomes of some cytoplasmic RNA viruses are also m6A-modified.
Marco Giordano et al.
Journal of experimental & clinical cancer research : CR, 40(1), 319-319 (2021-10-15)
Cancer stem cells (CSC) have been implicated in tumor progression. In ovarian carcinoma (OC), CSC drive tumor formation, dissemination and recurrence, as well as drug resistance, thus contributing to the high death-to-incidence ratio of this disease. However, the molecular basis

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務